I
ntegrins are a family of large cell surface adhesion molecules composed of noncovalently linked ␣ and ␤ subunits that mediate cell-to-cell, cell-to-extracellular-matrix, and cell-to-pathogen interactions (1) (2) (3) (4) (5) . They respond dynamically to a wide variety of signals and act as key regulators of many cellular processes. In the classical ''outside-in'' signaling process, ligand binding induces conformational changes of integrins and then transduces signals from the extracellular domain to the cytoplasm. In the ''inside-out'' signaling process (also called priming), intracellular signals impinge on the cytoplasmic domains of integrins and then alter their adhesiveness for extracellular ligands. These dynamic properties of integrins are critical to their proper functions.
Lymphocyte function-associated antigen 1 (LFA-1, ␣ L ␤ 2 or CD11a/CD18) consisting of an ␣ L subunit of 180 kDa and a ␤ 2 subunit of 95 kDa, belongs to the ␤ 2 integrin subfamily, which contains 4 members characterized by a common ␤ 2 subunit (6). These ␤ 2 integrins are widely expressed in the immune system and play important roles in immune cell adhesion, trafficking, and activation (7, 8) . LFA-1 is present on all leukocytes and recognizes intercellular adhesion molecules (ICAMs), which are members of the Ig superfamily (9) . ICAM-1 is highly inducible on antigenpresenting cells and endothelium by cytokines in inflammation and is the most important ligand for LFA-1-dependent adhesion of B, T, and myeloid cells (10) . The ligand-binding site for ICAM-1 in LFA-1 has been mapped to an Ϸ180-residue region of the ␣ L subunit entitled inserted (I) domain (3, 11) , which has also been shown to be a key ligand-binding domain in many other integrins (12, 13) . The ␣ L I domain assumes a typical Rossmann fold and contains a conserved metal ion-dependent adhesion site (MIDAS) consisting of residues Asp-137-Ser-141, Thr-206, and Asp-239 at the C-terminal end of the central ␤-sheet, which is the binding site for ligands (14, 15 (5, 11, (15) (16) (17) (18) (19) (20) .
Because LFA-1 plays important roles in many cellular processes, disorder of its functions can cause serious autoimmune and inflammatory diseases and is implicated in multiple cancers including myeloma, malignant lymphoma, and acute and chronic leukemias (21) (22) (23) (24) (25) . Thus, it has become a therapeutic target for the treatment of multiple autoimmune and inflammatory diseases and cancers (8, 26, 27) . Psoriasis is a very common skin disease that is characterized by red or salmon pink color, white or silver scaly and raised plaques (22) . Although the cause of psoriasis remains an enigma, it has become increasingly clear that the activity of the lymphocytic infiltrate consisting primarily of T cells is the driving force for induction of the changes in psoriasis and is also required for maintenance of the plaques (28) .
On the basis of the pathogenesis of psoriasis, therapies targeted at T cells have been designed and applied. Among many antiCD11a monoclonal antibodies (29) (30) (31) (32) (33) (34) , murine monoclonal antibody (mAb) MHM24 was developed to a recombinant, humanized monoclonal IgG 1 antibody Efalizumab (Raptiva, Genentech) (35) , which has become one of the most efficacious drugs for treating psoriasis. Efalizumab was shown to be efficacious in treating patients with psoriasis (36) and can inhibit the extravasation and (re-)activation of T lymphocytes, and their interactions with keratinocytes (37) . MHM24 binds specifically to LFA-1 and blocks the binding of ICAM-1 (38, 39) . The epitope of MHM24 was mapped to the region containing residues Lys-197 to His-201 of the ␣ L I domain of LFA-1 (29) .
To investigate the structural basis of the recognition and binding of Efalizumab with LFA-1 and the molecular mechanism of inhibition of LFA-1 by Efalizumab, we determined the crystal structures of the Efalizumab Fab fragment alone and in complex with the ␣ L I domain of LFA-1. The Efalizumab Fab binds to the I domain mainly via the 3 heavy-chain complementarity determining regions (CDRs). The epitope on the I domain for Efalizumab is located nearby but does not overlap with the MIDAS. The binding of Efalizumab does not occlude the binding site for ICAM-1, but the light chain of the Fab occupies the spatial position of ICAM-1 domain 2 in the ICAM-1/I domain complex, thus preventing ICAM-1 domain 1 from accessing the ligand-binding site of the I domain. Our structural data suggest that Efalizumab binding blocks the binding of LFA-1 to ICAM-1 via steric hindrance and thus inhibits the activities of LFA-1. These findings provide a structural basis for the development of improved antibodies and new strategies for treatment of psoriasis and other autoimmune diseases.
Results and Discussion
Structures of the Efalizumab Fab Alone and in Complex with the LFA-1 ␣L I Domain. The crystal structure of the Efalizumab Fab alone was determined by the molecular replacement (MR) method and refined to 1.8 Å resolution (Table 1) . There is 1 Fab molecule in the asymmetric unit, consisting of residues 1-213 of the light chain and residues 1-136 and 142-219 of the heavy chain. The Efalizumab Fab has a canonical immunoglobin fold consisting of 4 ␤-barrel domains (Fig. 1A) . The elbow angle of the Fab, defined as the subtended angle by the 2 pseudo 2-fold axes relating V H to V L and C H to C L , was calculated as 185.5°, consistent with the observation that Efalizumab has a light chain (35, 40) . The complementarity determining regions (CDRs) are clearly defined in this antigen-free structure. The H3 loop lies between the light-chain CDRs L1, L2, and L3 and the heavy-chain CDRs H1 and H2, and has both hydrophobic and hydrophilic interactions with the other CDRs.
The Fab/I domain complex can be crystallized in 2 crystal forms.
Crystals of form I belong to space group P2 1 2 1 2 1 and can diffract to 2.8 Å resolution (Table 1) , and crystals of form II belong to space group P6 1 22 and can diffract to 3.6 Å resolution (Table S1 ). Both structures of the protein complex were solved using the MR method and contain 2 Fab/I domain complexes in the asymmetric unit, consisting of the Fab light-chain residues 1-214 and heavy-chain residues 1-136 and 142-220, and the I domain residues 128-306 ( Fig. 1 A) . There is a Zn 2ϩ atom bound at the MIDAS of each I domain in the form II complex structure, but no metal ion was identified in the form I complex structure. 
‡ R ϭ ͚hkl͉͉Fo͉Ϫ͉Fc͉͉/͚hkl͉Fo͉. Fab undergoes a dramatic change (185.5°in the free form and 132.5°-137.5°with a slight variation in the complex structures). Crystal packing analyses indicate that both the V and C domains are involved in interactions with symmetry-related molecules in both the free form and the complex. In addition, superposition of the V domains (residues 1-107 of the light chain and 1-120 of the heavy chain) of the Fab in the free form and the complex reveals an RMSD of 0.51 Å and superposition of the C domains (residues 108-213 of the light chain and 121-219 of the heavy chain) an RMSD of 0.65 Å, respectively. Furthermore, the 6 CDRs of the Fab in the free form and the complex adopt almost identical conformations. These results indicate that the binding of the I domain does not cause evident conformational changes of the CDRs and the V and C domains. Thus, it is very likely that the change of the elbow angle is caused by crystal packing due to the inherent flexibility of the elbow (40) . The LFA-1 ␣ L I domain in the complex assumes the classic Rossmann fold, consisting of a central parallel ␤-sheet of 5 ␤-strands and an additional antiparallel ␤-strand, surrounded on both sides by amphipathic ␣-helices (Fig. 1 A) . Comparison with the previously reported structures of the ␣ L I domain shows that the I domain in this complex assumes a conformation similar to the closed, low-affinity conformation of the unliganded I domain (an RMSD of 0.40-0.60 Å) (18) rather than the open conformation of the I domain in complex with ICAM-1 (an RMSD of 1.65 Å) (11) (Fig. 1B) . Specifically, both the MIDAS (residues Asp-137-Ser-141, Thr-206, and Asp-239) which is the binding site for ICAM-1 and the C-terminal ␣-helix ␣7, which undergoes major conformational change to activate LFA-1 when ICAM-1 binds, adopt the conformations as seen in the unliganded I domain.
Interactions Between the Efalizumab Fab and the LFA-1 ␣L I Domain.
The interactions between the Efalizumab Fab and the LFA-1 ␣ L I domain involve primarily the 3 heavy-chain CDRs of the Fab and 2 ␣-helices ␣1 (residues 144-155) and ␣3 (residues 191-203) of the I domain ( Fig. 1 A and Fig. 2A ). In total, there are 111 van der Waals contacts and 10 hydrophilic interactions between 14 Fab residues and 14 I domain residues. The interaction interface buries 4.7% (1319.7 Å 2 ) of the total solvent accessible surface area (9135.9 Å 2 for the I domain and 19109.0 Å 2 for the Fab), which is within the range for other antibody-antigen interaction (41) . The shape complementarity statistics score (Sc) is 0.78, which is also higher than the average value (0.64-0.68) for other antibody-antigen complexes (42) . These results are in agreement with the high binding affinity of the Efalizumab Fab with the ␣ L I domain (K D ϭ 2.2 Ϯ 0.5 nM) (Fig. S1 ), which is comparable to that of the MHM24 Fab with the ␣ L I domain (K D ϭ 1.9 Ϯ 0.4 nM) (43) . It is noteworthy that the antibody-antigen interaction in the Efalizumab Fab/I domain complex relies almost exclusively on the 3 V H CDRs. In most of the antibody-antigen complexes, usually both V H and V L CDRs are involved in the antibody-antigen interaction with the V H CDRs playing a dominant role. A similar recognition mode of the antibody-antigen interaction with exclusive reliance on the V H CDRs has been observed in some other antibody-antigen complexes (44, 45) .
The 3 heavy-chain CDRs of the Fab form a large pocket to accommodate the epitope (Fig. 2 A) and make extensive hydrophobic interactions with the I domain (Table S2 ). In particular, residues of the H3 loop contribute more than half of the total van der Waals contacts (58 out of 111). In contrast, the light chain (Tyr-49 L of the L2 loop) has only 2 van der Waals contacts with Pro-144 I of the I domain. (Residues of the I domain are designated by a superscripted suffix I, those of the Fab heavy chain by H, and those of the Fab light chain by L, respectively. The Efalizumab Fab uses the sequential numbering scheme and the Kabat numbering scheme of the Fab is provided in Table S3 (46, 47) and aromatic residues usually make the majority of the hydrophobic interactions (48) .
In addition to these hydrophobic interactions, 2 negatively charged surface patches in the pocket play important roles in the recognition and binding of the I domain ( Fig. 2 B and C) H of the FWR-3 have moderate effects on the I domain binding. These 2 residues are located near the Efalizumab Fab/I domain interface, but have no direct interaction with the I domain. They appear to contribute to the conformational stabilization of the CDR loops. Furthermore, Gln-62 H and Lys-65 H of the H2 loop are suggested to be involved in the interactions with the I domain because their mutations have notable effects on the I domain binding (35) . These 2 residues are located distantly from the interaction interface and may contribute indirectly to the stabilization of the conformations of the CDR loops. The mutagenesis data also showed that in addition to the heavy-chain CDRs, 3 light-chain L3 residues His-91 L , Asn-92 L , and Tyr-94 L are involved in the antibody-antigen interaction as well because their mutations can substantially impair the binding of Efalizumab to the I domain. In the complex structure, these residues have no direct interaction with the I domain, but have interactions with the H3 loop. Mutations of these residues would alter the conformation of the H3 loop and thus affect the binding of the I domain.
The Efalizumab Epitope on the ␣L I Domain Is Distinct from the MIDAS.
Analyses of the free Fab structure and the Fab/I domain complex structure indicate that the Efalizumab epitope on the LFA-1 ␣ L I domain is composed of the ␣-helices ␣1 and ␣3, and the conformation of the epitope is not altered upon the Fab binding. The MIDAS, which is the binding site for ICAM-1 comprises a DxSxS sequence (residues 137-141) from the ␤1-␣1 loop, Thr-206 from the ␣3-␣4 loop, and Asp-239 from the ␤4-␣5 loop. The epitope is located nearby but does not overlap with the MIDAS (the distance between Lys-200 I of the epitope and Zn 2ϩ at the MIDAS is about 15 Å) (Fig. 1 A) . In particular, residues Lys-197 I , Lys-200 I , and His-201 I of ␣-helix ␣3 contribute almost half of the hydrophobic interactions (50 out of 111) and more than half of the hydrophilic interactions (8 out of 10) and are the determinants for the specific recognition of the ␣ L I domain by Efalizumab. These results are consistent with and provide a structural basis for the biochemical data in mapping the epitope of the ␣ L I domain recognized by MHM24, the originating murine antibody of Efalizumab, showing that mutation K197D in the ␣ L I domain completely abolished the binding with MHM24 and mutations K200D and H201A significantly diminished the binding, whereas mutations of other residues had very minor effects on the binding (29) . Sequence alignment of the I domains of all 9 known ␣ subunit-containing integrins (5) shows that Lys-197 ⌱ has a counterpart only in the ␣ 1 , ␣ 10 , and ␣ M I domains and Lys-200 ⌱ and His-201 ⌱ do not exist at the equivalent positions in the other I domains (Fig. 2D) . This explains why Efalizumab can only bind specifically to the ␣ L I domain but not other I domains. (Fig. 3A) . In other words, Efalizumab does not directly block domain 1 of ICAM-1 to access the ligand-binding site of the I domain, but the Fab light chain occupies the spatial position of domain 2 of ICAM-1 and thus prevents domain 1 from reaching the MIDAS. Thus, with Efalizumab bound to the I domain, ICAM-1 cannot bind to the I domain. Because the interactions between domain 1 and domain 2 of ICAM-1 are not very strong and the interdomain conformation can vary slightly in free form and in complex with the ␣ L I domain (11, 49, 50) , to examine the possibility of whether the steric clashes between the Efalizumab Fab and the ICAM-1 domain 2 could be avoided by interdomain movement of ICAM-1, we superimposed all structures of ICAM-1 with different interdomain conformations available in the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) onto that of the aforementioned superimposed ICAM-1/I domain complex based on domain 1 of ICAM-1 (residues 1-82) (Fig. 3A) . The results clearly show that for these interdomain conformations observed in the structures of ICAM-1 reported so far, the spatial clashes between the Fab light chain and the ICAM-1 domain 2 cannot be avoided.
On the basis of these results, we propose the inhibition mechanism of LFA-1 by Efalizumab (Fig. 3B) . The binding of Efalizumab to the LFA-1 ␣ L I domain does not occlude the binding site for ICAM-1; instead it blocks the binding of ICAM-1 via steric hindrance between the Fab light chain and the ICAM-1 domain 2 and thus inhibits the activities of LFA-1. This inhibition mechanism is reminiscent of that of epidermal growth factor receptor (EGFR) by Matuzumab (51) . The binding of Matuzumab to domain III of EGFR does not occlude the binding site for EGF, but causes steric clashes between the light chain of the Matuzumab Fab and the N-terminal region of domain I of EGFR and thus prevents the local conformational changes and domain rearrangement that are required for high-affinity ligand binding and receptor dimerization. However, the inhibition mechanism of LFA-1 by Efalizumab is different from that of the ␣ 1 ␤ 1 integrin by the AQC2 antibody (52) . AQC2 binds to the MIDAS of the ␣ 1 I domain, and thus prevents directly the binding of the natural ligand at the MIDAS and inhibits the activities of the integrin.
In addition to Efalizumab, a number of antibodies have been reported that can bind specifically to the LFA-1 I domain and inhibit the LFA-1 activity. In the Efalizumab Fab/I domain complex the epitope for Efalizumab consists of residues of ␣1 (residues 144-155) and ␣3 (residues 191-203). Previous biochemical studies have shown that F8.8 and CBR-LFA-1/9 recognize Pro-144 I , Lys-200 I , and His-201 I (30, 33, 34 I , and Leu-203 I . These inhibitory antibodies share their epitope residues with those for Efalizumab and thus are likely to use a similar inhibition mechanism as that by Efalizumab. In addition, several other inhibitory mAbs also recognize the same epitope regions as those for Efalizumab, including CLB-LFA-1/2, 32E6, and 50G1 (29, 31) . Furthermore, there are a number of other inhibitory mAbs that bind to the LFA-1 I domain but recognize epitopes different from that for Efalizumab. For example, antibodies TS1/22, TS2/14, and 25-3-1 recognize residues of the ␤5-␣6 loop and helix ␣6 of the I domain (34) . These mAbs appear to employ a different inhibition mechanism from that by Efalizumab.
Implications for Therapeutic Applications. The structure of the Efalizumab Fab/I domain complex has revealed the detailed interactions between the antibody and the epitope. These structural data provide valuable information for the development of improved antibodies against psoriasis. On the basis of the complex structure, we could design changes of some residues on the CDRs of the Fab that could make favorable interactions and/or avoid unfavorable interactions with residues of the I domain to improve its binding affinity and specificity with LFA- Besides, our structural results could be used in the development of new therapeutic antibodies that target a similar region of the ␣ I domain of other integrins against other autoimmune diseases and cancers. In addition, our findings could be exploited in designing new therapeutic strategies for the treatment of psoriasis and other autoimmune diseases and cancers. Since the epitope of the LFA-1 ␣ L I domain by Efalizumab is distinct from the MIDAS and the binding sites for some other antibodies and antagonists, it might be advantageous to apply Efalizumab in combination with other drugs (antagonists or antibodies) that target different sites of the ␣ L I domain to achieve synergistic or optimal therapeutic effect.
Methods
Protein Preparation. The Fab fragment of Efalizumab was obtained by papain digestion of the Raptiva antibody (Genentech/Xoma). The digested protein sample was loaded onto a Protein A Sepharose 4 FF column (GE Healthcare), and the Fab fragment eluted in the flow through was separated from the Fc fragment and further purified with ion exchange chromatography using a Q-Sepharose FF column (GE Healthcare). The protein sample was concentrated to about 10 mg/mL and then exchanged to a stock buffer (10 mM Tris-HCl, pH 8.0, and 100 mM NaCl) for crystallization.
The cDNA sequence encoding residues Gly-128 -Val-308 of human LFA-1 ␣L I domain with an enterokinase (EK) cleavage site (DDDDK) at the 5Ј-end was cloned into the pET32a vector (Novagen), which contains a thioredoxin (Trx) tag at the N terminus. The plasmid was transformed into Escherichia coli BL21(DE3) cells (Novagen). The transformed cells were grown in LB medium at 37°C until OD600 reached 1.5 and expression of the protein was induced with 0.5 mM IPTG for 4 h at 20°C. The bacterial cells were incubated in a lysis buffer (PBS, PBS) containing 1 mg/mL lysozyme, 1 mM PMSF, and 1% Triton X-100 for 20 min at 0°C followed by sonication. The cell lysate was precipitated by centrifugation (10,000 g) and filtration (0.45 m). The supernatant was purified with an Ni-NTA column (Novagen). The target protein was eluted with the lysis buffer supplemented with 0.4 M imidazole and the eluted sample was exchanged into 50 mM Tris-HCl, pH 8.0, and 50 mM NaCl with a Sephadex G-25 desalting column. For EK digestion, CaCl2 was added to the purified Trx-I domain fusion protein solution to a final concentration of 2 mM, and the mixture was incubated with recombinant EK (light chain) (Zhangjiang Biotech). The Trx-I domain fusion protein was digested by EK at 1 mg protein/1 U enzyme and incubated overnight at 21°C. The digested protein sample was loaded onto an Ni-NTA column (Novagen) and the I domain eluted in the flow through was separated from the Trx tag and undigested fusion protein. The I domain was further purified with ion exchange chromatography using a Q-Sepharose FF column (GE Healthcare).
To prepare a homogenous Fab/I domain complex, the protein samples of the Efalizumab Fab and the ␣L I domain were mixed, concentrated and then loaded onto a Superdex 200 column (GE Healthcare). The protein complex was eluted in 20 mM Tris-HCl (pH 7.9) and concentrated to Ϸ15 mg/mL for crystallization. The concentrations of the protein samples were measured using a Bio-Rad protein assay kit and the purity and homogeneity were confirmed by SDS/PAGE and dynamic light scattering analyses. Crystal of the Fab alone was cryoprotected using the reservoir solution supplemented with 20% glycerol and then flash cooled into the liquid N2 stream (Ϫ170°C). Diffraction data were collected using a Rigaku R-AXIS IVϩϩ diffractometer and processed with the CrystalClear suite (53) . Crystal of the Fab/I domain complex of form I was cryoprotected using Paratone-N (Hampton Research) and crystal of form II was dehydrated against 50% wt/vol PEG 8000, and then flash cooled into the liquid N2 stream (Ϫ170°C). Diffraction data of the protein complex of form I were collected at beamline NW12 and that of form II at beamline 17A of Photon Factory, Japan. Both data sets were processed with the HKL2000 suite (54) . The statistics of the diffraction data are summarized in Table  1 and Table S1 .
Crystallization and Diffraction Data
Structure Determination and Refinement. Both structures of the Efalizumab Fab alone and in complex with the LFA-1 I domain were solved with the MR method using a combination of the programs CNS (55) and Phaser (56) . For the structure of the free Fab fragment, the structure of the antibody AF2 Fab (PDB code 1B2W) was used as the search model. For the structure of the protein complex of form I, the structures of the antibody 29G11 Fab (PDB code 1A0Q) and the ␣L I domain (PDB code 1ZOP) were used as the search models. For the structure of the protein complex of form II, the complex structure of form I was used as the search model. Structure refinement was carried out using CNS and model building was facilitated with the program Coot (57). The free Fab structure contains one Fab molecule and both complex structures contain 2 Fab/I domain complexes in the asymmetric unit. In the complex structure of form I, there was no evident electron density at the MIDAS of the I domain in both complexes. In the complex structure of form II, there was strong electron density at the MIDAS of both I domains which was putatively modeled as a Zn 2ϩ ion because only Zn 2ϩ was added in the crystallization solution. Electron density peaks at a height of at least 2.5 in difference Fourier maps were assigned as water molecules if they had reasonable geometry in relation to hydrogen bond donors or acceptors and had B factor of less than 60 Å 2 after subsequent refinement.
Accession Codes.
Coordinates of the structures of the Efalizumab Fab alone and in complex with the LFA-1 ␣L I domain in 2 different crystal forms have been deposited in the RCSB Protein Data Bank with accession codes 3EO9, 3EOA, and 3EOB, respectively.
